drugset / Trial / NCT02687542

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT02687542

Phase 2 Terminated 108 enrolled Pfizer
RandomizedTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Timeline

Start
2016-03-03
Primary completion
2017-11-10
Completion
2017-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavapadon Small molecule 1 mg
Subject Tavapadon Small molecule 3 mg
Subject Tavapadon Small molecule 7 mg
Subject Tavapadon Small molecule 15 mg

Indications